Berta Saez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Berta Saez has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Antonio Roman
9 shared publications- Rosalía Laporta
Department of Pulmonology and Lung Transplantation, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
9 shared publications Alexandra Baiges
8 shared publicationsAnna Villar-Piqué
8 shared publicationsCarmen Herranz
8 shared publicationsClaudia Valenzuela
8 shared publications
Latest Publications
- 11 August 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , e197-e220
Baseline Lung Allograft Dysfunction: Definition, Timing, and Implications for Outcomes—an ISHLT Consensus Document
- 11 August 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (10) , e197-e220
Baseline Lung Allograft Dysfunction: Definition, Timing, and Implications for Outcomes—an ISHLT Consensus Document
- 2 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2502380
A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction
Background: Chronic lung allograft dysfunction (CLAD) is the leading cause of late mortality after lung transplantation. Bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS) are the main underlying clinical entities. Their molecular and cellular signatures are unclear and, therefore, we aimed to identify molecular programmes associated with morphological disease severity in CLAD. Methods: We performed high-resolution imaging-based gene expression profiling of 128 lung samples from explanted CLAD and donor lungs, using weighted gene co-expression network analysis, cellular and pathway enrichment, and hub gene identification. Findings were validated across four datasets, including a murine transplant model, human BOS lungs, transbronchial biopsies, and bronchoalveolar lavage fluid of lung transplant recipients. Results: Unsupervised clustering revealed two transcriptomic CLAD endotypes aligning with mild-fibrotic (BOS, mild RAS) and advanced-fibrotic disease (moderate/severe RAS). Samples from the same patient often diverged molecularly, underscoring intra-patient heterogeneity and limitations of current phenotypical classification. Five molecular programmes emerged: (1) epithelial stress and innate immunity in early-fibrotic CLAD, (2) progressive adaptive immunity and cytotoxicity in advanced CLAD, (3) transient extracellular matrix remodelling, (4) progressive endothelial loss/dysfunction, and (5) progressive loss of homeostasis, wherein multiple potential druggable targets were detected. Finally, we identified a 26 CLAD hub gene-panel, that showed robust diagnostic performance to discriminate CLAD. Conclusion: CLAD is a spatially heterogeneous, yet molecularly continuous disease process, wherein BOS and RAS represent variable stages of a shared immunopathological continuum. Our findings support the development of lung-specific molecular classifiers to guide diagnostics and reveal novel targets for personalised therapies in transplantation.
- 2 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2502380
A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction
Background: Chronic lung allograft dysfunction (CLAD) is the leading cause of late mortality after lung transplantation. Bronchiolitis obliterans syndrome (BOS) and restrictive allograft syndrome (RAS) are the main underlying clinical entities. Their molecular and cellular signatures are unclear and, therefore, we aimed to identify molecular programmes associated with morphological disease severity in CLAD. Methods: We performed high-resolution imaging-based gene expression profiling of 128 lung samples from explanted CLAD and donor lungs, using weighted gene co-expression network analysis, cellular and pathway enrichment, and hub gene identification. Findings were validated across four datasets, including a murine transplant model, human BOS lungs, transbronchial biopsies, and bronchoalveolar lavage fluid of lung transplant recipients. Results: Unsupervised clustering revealed two transcriptomic CLAD endotypes aligning with mild-fibrotic (BOS, mild RAS) and advanced-fibrotic disease (moderate/severe RAS). Samples from the same patient often diverged molecularly, underscoring intra-patient heterogeneity and limitations of current phenotypical classification. Five molecular programmes emerged: (1) epithelial stress and innate immunity in early-fibrotic CLAD, (2) progressive adaptive immunity and cytotoxicity in advanced CLAD, (3) transient extracellular matrix remodelling, (4) progressive endothelial loss/dysfunction, and (5) progressive loss of homeostasis, wherein multiple potential druggable targets were detected. Finally, we identified a 26 CLAD hub gene-panel, that showed robust diagnostic performance to discriminate CLAD. Conclusion: CLAD is a spatially heterogeneous, yet molecularly continuous disease process, wherein BOS and RAS represent variable stages of a shared immunopathological continuum. Our findings support the development of lung-specific molecular classifiers to guide diagnostics and reveal novel targets for personalised therapies in transplantation.
- Open Access
- 10 June 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (6) , e0155625
Diagnostic value of galactomannan in tracheobronchial aspirate for Aspergillus infection in lung transplant recipients (the GALACTBAS study)
Lung transplant recipients (LTR) are highly susceptible to Aspergillus infection (AI), but diagnosis may be limited by the invasiveness of bronchoalveolar lavage fluid (BALF) collection. Proximal airway samples may provide a less invasive alternative. We conducted a retrospective single-center study including all adult LTR (March 2018–March 2022) who underwent bronchoscopy with tracheobronchial aspirate (TBA) and BALF galactomannan (GM) testing in the same procedure. They were processed for mycological culture and EIA-based GM (Bio-Rad) after cysteine homogenization. AI was defined according to ISHLT consensus. A ROC curve for TBA GM and its diagnostic performance were assessed. A total of 545 paired TBA–BALF samples from 282 LTR were analyzed. Proven or probable AI was diagnosed in 22 samples (4%). The optimal TBA GM cut-off was ≥0.54 optical density index (ODI), yielding 95.2% sensitivity, 92% specificity, and an AUC of 0.97 (95% CI, 0.95–0.99). In comparison, BALF GM at ≥1.0 ODI showed 33.3% sensitivity and 99.6% specificity (AUC 0.88, 95% CI, 0.80–0.95) although BALF GM values were significantly higher in invasive infections compared with non-invasive infections (1.49 vs 0.14; P -value = 0.007). TBA cultures were more frequently positive than BALF (24% vs 9.9%). Finally, TBA and BALF GM values demonstrated moderate correlation ( r = 0.54), and combined testing with concordant results improved accuracy to 99.6%. TBA GM demonstrated higher sensitivity than BALF GM for detecting AI in LTR, while maintaining high specificity. Proximal airway samples could complement BALF in future diagnostic strategies. IMPORTANCE: This study provides evidence that galactomannan antigen testing (GM) in tracheobronchial aspirate (TBA) is a highly sensitive, reliable, and less invasive diagnostic tool for detecting Aspergillus infection in lung transplant recipients under universal antifungal prophylaxis, compared to the current standard bronchoalveolar lavage fluid (BALF) GM. These findings highlight the diagnostic value of proximal airway specimens, consistent with the pathophysiology of post-transplant aspergillosis, which often originates in the bronchial tree and may not be adequately captured by BALF early in the disease course. Importantly, the study shows that combining TBA and BALF GM results yields near-perfect diagnostic accuracy, supporting a complementary diagnostic strategy rather than a replacement approach. Although this is a proof-of-concept study, it fills a critical evidence gap in transplant infectious diseases and lays the groundwork for safer, more accurate, and earlier diagnosis of Aspergillus infection, with potential implications for clinical practice, antifungal stewardship, and future guideline development.
- 10 June 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (6) , e0155625
Open AccessDiagnostic value of galactomannan in tracheobronchial aspirate for Aspergillus infection in lung transplant recipients (the GALACTBAS study)
Lung transplant recipients (LTR) are highly susceptible to Aspergillus infection (AI), but diagnosis may be limited by the invasiveness of bronchoalveolar lavage fluid (BALF) collection. Proximal airway samples may provide a less invasive alternative. We conducted a retrospective single-center study including all adult LTR (March 2018–March 2022) who underwent bronchoscopy with tracheobronchial aspirate (TBA) and BALF galactomannan (GM) testing in the same procedure. They were processed for mycological culture and EIA-based GM (Bio-Rad) after cysteine homogenization. AI was defined according to ISHLT consensus. A ROC curve for TBA GM and its diagnostic performance were assessed. A total of 545 paired TBA–BALF samples from 282 LTR were analyzed. Proven or probable AI was diagnosed in 22 samples (4%). The optimal TBA GM cut-off was ≥0.54 optical density index (ODI), yielding 95.2% sensitivity, 92% specificity, and an AUC of 0.97 (95% CI, 0.95–0.99). In comparison, BALF GM at ≥1.0 ODI showed 33.3% sensitivity and 99.6% specificity (AUC 0.88, 95% CI, 0.80–0.95) although BALF GM values were significantly higher in invasive infections compared with non-invasive infections (1.49 vs 0.14; P -value = 0.007). TBA cultures were more frequently positive than BALF (24% vs 9.9%). Finally, TBA and BALF GM values demonstrated moderate correlation ( r = 0.54), and combined testing with concordant results improved accuracy to 99.6%. TBA GM demonstrated higher sensitivity than BALF GM for detecting AI in LTR, while maintaining high specificity. Proximal airway samples could complement BALF in future diagnostic strategies. IMPORTANCE: This study provides evidence that galactomannan antigen testing (GM) in tracheobronchial aspirate (TBA) is a highly sensitive, reliable, and less invasive diagnostic tool for detecting Aspergillus infection in lung transplant recipients under universal antifungal prophylaxis, compared to the current standard bronchoalveolar lavage fluid (BALF) GM. These findings highlight the diagnostic value of proximal airway specimens, consistent with the pathophysiology of post-transplant aspergillosis, which often originates in the bronchial tree and may not be adequately captured by BALF early in the disease course. Importantly, the study shows that combining TBA and BALF GM results yields near-perfect diagnostic accuracy, supporting a complementary diagnostic strategy rather than a replacement approach. Although this is a proof-of-concept study, it fills a critical evidence gap in transplant infectious diseases and lays the groundwork for safer, more accurate, and earlier diagnosis of Aspergillus infection, with potential implications for clinical practice, antifungal stewardship, and future guideline development.
- Open Access
- 1 January 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (179) , 250298
Anti-HLA antibodies in lung transplantation: diagnostic pitfalls and future directions
Lung transplant recipients face high rejection rates, causing significant disease burden and limiting long-term outcomes. Among immunological factors affecting lung allografts, anti-human leukocyte antigen (HLA) antibodies, particularly donor-specific anti-HLA antibodies (DSAs), are key mediators of antibody-mediated rejection. Yet, the biology, detection and interpretation of DSAs remain incompletely defined across the pre-, peri- and post-transplant continuum. HLAs are highly polymorphic immune recognition molecules, and donor–recipient mismatches drive alloimmune responses. HLA typing is used to assess genetic disparity, but low-resolution approaches risk misclassifying mismatches and DSAs, whereas high-resolution typing improves diagnostic accuracy yet is not universally implemented. Standard HLA antibody monitoring assays report median fluorescence intensity. However, median fluorescence intensity does not convey information on the affinity, avidity or functional capacity of these antibodies, and may be affected by technical factors such as bead saturation, the Hook effect or binding to denatured HLAs. Subclass profiling adds further complexity: IgG1 and IgG3 are potent complement activators, whereas IgG2 and IgG4 have weaker or regulatory roles and differ in clearance by apheresis. Functional assays, including C1q- or C3d-binding HLA antibody detection assays and emerging endothelial or natural killer-cell-based platforms, offer additional insights into antibody-binding, complement activation and cytotoxic potential, but are not routinely applied in current clinical practice. Prospective mechanistic studies are required to define the clinical benefit, cost-effectiveness and optimal integration of these advanced immunological tools into routine practice pre-, peri- and post-lung transplant. DSAs drive lung allograft injury, yet their detection and interpretation remain inconsistent. Implementation of high-resolution HLA typing and functional assays may improve risk assessment and guide future clinical practice.
- 1 January 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (179) , 250298
Open AccessAnti-HLA antibodies in lung transplantation: diagnostic pitfalls and future directions
Lung transplant recipients face high rejection rates, causing significant disease burden and limiting long-term outcomes. Among immunological factors affecting lung allografts, anti-human leukocyte antigen (HLA) antibodies, particularly donor-specific anti-HLA antibodies (DSAs), are key mediators of antibody-mediated rejection. Yet, the biology, detection and interpretation of DSAs remain incompletely defined across the pre-, peri- and post-transplant continuum. HLAs are highly polymorphic immune recognition molecules, and donor–recipient mismatches drive alloimmune responses. HLA typing is used to assess genetic disparity, but low-resolution approaches risk misclassifying mismatches and DSAs, whereas high-resolution typing improves diagnostic accuracy yet is not universally implemented. Standard HLA antibody monitoring assays report median fluorescence intensity. However, median fluorescence intensity does not convey information on the affinity, avidity or functional capacity of these antibodies, and may be affected by technical factors such as bead saturation, the Hook effect or binding to denatured HLAs. Subclass profiling adds further complexity: IgG1 and IgG3 are potent complement activators, whereas IgG2 and IgG4 have weaker or regulatory roles and differ in clearance by apheresis. Functional assays, including C1q- or C3d-binding HLA antibody detection assays and emerging endothelial or natural killer-cell-based platforms, offer additional insights into antibody-binding, complement activation and cytotoxic potential, but are not routinely applied in current clinical practice. Prospective mechanistic studies are required to define the clinical benefit, cost-effectiveness and optimal integration of these advanced immunological tools into routine practice pre-, peri- and post-lung transplant. DSAs drive lung allograft injury, yet their detection and interpretation remain inconsistent. Implementation of high-resolution HLA typing and functional assays may improve risk assessment and guide future clinical practice.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Figure S1: UMAP projection of LAM lung tissue scRNA-seq data, and zoom-in of the LAM and lung mesenchymal cell cluster. Figure S2: Positive controls of immunohistochemical assays. Figure S3: Unsupervised hierarchical clustering of expression differences of LAMp genes between LAM lung nodules and melanoma or pulmonary arterial smooth muscle cells. Figure S4: LAMcore correlation with ER-target and PR/ER-target signatures in LAM cells with low and high LAMcore scores. Figure S5: A, LAMp-LAMcore score correlations and unsupervised hierarchical clustering in normal-adjacent and primary tissue of 15 TCGA cancer studies. Figure S6: IRF1 and RUNX1 loci association results with spirometry measures.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Figure S1: UMAP projection of LAM lung tissue scRNA-seq data, and zoom-in of the LAM and lung mesenchymal cell cluster. Figure S2: Positive controls of immunohistochemical assays. Figure S3: Unsupervised hierarchical clustering of expression differences of LAMp genes between LAM lung nodules and melanoma or pulmonary arterial smooth muscle cells. Figure S4: LAMcore correlation with ER-target and PR/ER-target signatures in LAM cells with low and high LAMcore scores. Figure S5: A, LAMp-LAMcore score correlations and unsupervised hierarchical clustering in normal-adjacent and primary tissue of 15 TCGA cancer studies. Figure S6: IRF1 and RUNX1 loci association results with spirometry measures.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Table S2. A, Differentially expressed LAMp genes between non-LAM and LAM cells (FDR < 5%; Guo dataset). B, Differential gene expression between LAM cells with low and high LAMcore values (all genes considered). C, Curated gene sets positively correlated (FDR < 5%) with LAMcore in LAM cells. D, Curated gene sets negatively correlated (FDR < 5%) with LAMcore in LAM cells. E, Curated gene sets positively correlated (FDR < 5%) with LAMp in LAM cells. F, Curated gene sets negatively correlated (FDR < 5%) with LAMp in LAM cells. G, Overexpressed genes (n = 50) in depicted six cancer cell lines and LAM cells, relative to all other cancer cell lines analyzed. H, Overrepresented GO terms and KEGG pathways in the 50 genes commonly overexpressed in the six cancer cell lines and LAM cells. I, Overrepresented transcription factor binding sites in LAMp and LAMcore signatures. J, Overrepresented GO terms and KEGG pathways (FDR < 5%) in 10% of the most variably expressed genes among bulk LAM lung samples. K, Inferred immune cell contents in bulk LAM lung nodules (n = 14; GEO GSE12027) using CIBERSORTx.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Table S2. A, Differentially expressed LAMp genes between non-LAM and LAM cells (FDR < 5%; Guo dataset). B, Differential gene expression between LAM cells with low and high LAMcore values (all genes considered). C, Curated gene sets positively correlated (FDR < 5%) with LAMcore in LAM cells. D, Curated gene sets negatively correlated (FDR < 5%) with LAMcore in LAM cells. E, Curated gene sets positively correlated (FDR < 5%) with LAMp in LAM cells. F, Curated gene sets negatively correlated (FDR < 5%) with LAMp in LAM cells. G, Overexpressed genes (n = 50) in depicted six cancer cell lines and LAM cells, relative to all other cancer cell lines analyzed. H, Overrepresented GO terms and KEGG pathways in the 50 genes commonly overexpressed in the six cancer cell lines and LAM cells. I, Overrepresented transcription factor binding sites in LAMp and LAMcore signatures. J, Overrepresented GO terms and KEGG pathways (FDR < 5%) in 10% of the most variably expressed genes among bulk LAM lung samples. K, Inferred immune cell contents in bulk LAM lung nodules (n = 14; GEO GSE12027) using CIBERSORTx.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Lymphangioleiomyomatosis (LAM) is a rare, low-grade metastasizing disease characterized by cystic lung destruction. LAM can exhibit extensive heterogeneity at the molecular, cellular, and tissue levels. However, the molecular similarities and differences among LAM cells and tissue, and their connection to cancer features are not fully understood. By integrating complementary gene and protein LAM signatures, and single-cell and bulk tissue transcriptome profiles, we show sources of disease heterogeneity, and how they correspond to cancer molecular portraits. Subsets of LAM diseased cells differ with respect to gene expression profiles related to hormones, metabolism, proliferation, and stemness. Phenotypic diseased cell differences are identified by evaluating lumican (LUM) proteoglycan and YB1 transcription factor expression in LAM lung lesions. The RUNX1 and IRF1 transcription factors are predicted to regulate LAM cell signatures, and both regulators are expressed in LAM lung lesions, with differences between spindle-like and epithelioid LAM cells. The cancer single-cell transcriptome profiles most similar to those of LAM cells include a breast cancer mesenchymal cell model and lines derived from pleural mesotheliomas. Heterogeneity is also found in LAM lung tissue, where it is mainly determined by immune system factors. Variable expression of the multifunctional innate immunity protein LCN2 is linked to disease heterogeneity. This protein is found to be more abundant in blood plasma from LAM patients than from healthy women.Implications:This study identifies LAM molecular and cellular features, master regulators, cancer similarities, and potential causes of disease heterogeneity.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Lymphangioleiomyomatosis (LAM) is a rare, low-grade metastasizing disease characterized by cystic lung destruction. LAM can exhibit extensive heterogeneity at the molecular, cellular, and tissue levels. However, the molecular similarities and differences among LAM cells and tissue, and their connection to cancer features are not fully understood. By integrating complementary gene and protein LAM signatures, and single-cell and bulk tissue transcriptome profiles, we show sources of disease heterogeneity, and how they correspond to cancer molecular portraits. Subsets of LAM diseased cells differ with respect to gene expression profiles related to hormones, metabolism, proliferation, and stemness. Phenotypic diseased cell differences are identified by evaluating lumican (LUM) proteoglycan and YB1 transcription factor expression in LAM lung lesions. The RUNX1 and IRF1 transcription factors are predicted to regulate LAM cell signatures, and both regulators are expressed in LAM lung lesions, with differences between spindle-like and epithelioid LAM cells. The cancer single-cell transcriptome profiles most similar to those of LAM cells include a breast cancer mesenchymal cell model and lines derived from pleural mesotheliomas. Heterogeneity is also found in LAM lung tissue, where it is mainly determined by immune system factors. Variable expression of the multifunctional innate immunity protein LCN2 is linked to disease heterogeneity. This protein is found to be more abundant in blood plasma from LAM patients than from healthy women.Implications:This study identifies LAM molecular and cellular features, master regulators, cancer similarities, and potential causes of disease heterogeneity.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Figure S1: UMAP projection of LAM lung tissue scRNA-seq data, and zoom-in of the LAM and lung mesenchymal cell cluster. Figure S2: Positive controls of immunohistochemical assays. Figure S3: Unsupervised hierarchical clustering of expression differences of LAMp genes between LAM lung nodules and melanoma or pulmonary arterial smooth muscle cells. Figure S4: LAMcore correlation with ER-target and PR/ER-target signatures in LAM cells with low and high LAMcore scores. Figure S5: A, LAMp-LAMcore score correlations and unsupervised hierarchical clustering in normal-adjacent and primary tissue of 15 TCGA cancer studies. Figure S6: IRF1 and RUNX1 loci association results with spirometry measures.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Figure S1: UMAP projection of LAM lung tissue scRNA-seq data, and zoom-in of the LAM and lung mesenchymal cell cluster. Figure S2: Positive controls of immunohistochemical assays. Figure S3: Unsupervised hierarchical clustering of expression differences of LAMp genes between LAM lung nodules and melanoma or pulmonary arterial smooth muscle cells. Figure S4: LAMcore correlation with ER-target and PR/ER-target signatures in LAM cells with low and high LAMcore scores. Figure S5: A, LAMp-LAMcore score correlations and unsupervised hierarchical clustering in normal-adjacent and primary tissue of 15 TCGA cancer studies. Figure S6: IRF1 and RUNX1 loci association results with spirometry measures.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Table S2. A, Differentially expressed LAMp genes between non-LAM and LAM cells (FDR < 5%; Guo dataset). B, Differential gene expression between LAM cells with low and high LAMcore values (all genes considered). C, Curated gene sets positively correlated (FDR < 5%) with LAMcore in LAM cells. D, Curated gene sets negatively correlated (FDR < 5%) with LAMcore in LAM cells. E, Curated gene sets positively correlated (FDR < 5%) with LAMp in LAM cells. F, Curated gene sets negatively correlated (FDR < 5%) with LAMp in LAM cells. G, Overexpressed genes (n = 50) in depicted six cancer cell lines and LAM cells, relative to all other cancer cell lines analyzed. H, Overrepresented GO terms and KEGG pathways in the 50 genes commonly overexpressed in the six cancer cell lines and LAM cells. I, Overrepresented transcription factor binding sites in LAMp and LAMcore signatures. J, Overrepresented GO terms and KEGG pathways (FDR < 5%) in 10% of the most variably expressed genes among bulk LAM lung samples. K, Inferred immune cell contents in bulk LAM lung nodules (n = 14; GEO GSE12027) using CIBERSORTx.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue
Table S2. A, Differentially expressed LAMp genes between non-LAM and LAM cells (FDR < 5%; Guo dataset). B, Differential gene expression between LAM cells with low and high LAMcore values (all genes considered). C, Curated gene sets positively correlated (FDR < 5%) with LAMcore in LAM cells. D, Curated gene sets negatively correlated (FDR < 5%) with LAMcore in LAM cells. E, Curated gene sets positively correlated (FDR < 5%) with LAMp in LAM cells. F, Curated gene sets negatively correlated (FDR < 5%) with LAMp in LAM cells. G, Overexpressed genes (n = 50) in depicted six cancer cell lines and LAM cells, relative to all other cancer cell lines analyzed. H, Overrepresented GO terms and KEGG pathways in the 50 genes commonly overexpressed in the six cancer cell lines and LAM cells. I, Overrepresented transcription factor binding sites in LAMp and LAMcore signatures. J, Overrepresented GO terms and KEGG pathways (FDR < 5%) in 10% of the most variably expressed genes among bulk LAM lung samples. K, Inferred immune cell contents in bulk LAM lung nodules (n = 14; GEO GSE12027) using CIBERSORTx.